Global Nucleic Acid Drugs Competitive Landscape Professional Research Report 2025

Global Nucleic Acid Drugs Competitive Landscape Professional Research Report 2025

Research Summary

Nucleic acid drugs are a class of therapeutic agents that utilize nucleic acids, such as DNA or RNA, to treat diseases by targeting specific genetic sequences or processes within cells. These drugs can modulate gene expression, inhibit the production of disease-causing proteins, or correct genetic mutations responsible for various disorders. There are several types of nucleic acid drugs, including antisense oligonucleotides, small interfering RNA (siRNA), messenger RNA (mRNA), and gene editing tools like CRISPR-Cas9. Antisense oligonucleotides bind to target RNA molecules, preventing their translation into proteins or promoting their degradation. siRNA molecules silence specific genes by triggering RNA interference pathways, while mRNA therapies deliver exogenous mRNA to produce therapeutic proteins within cells. Gene editing tools like CRISPR-Cas9 enable precise modification of DNA sequences to correct genetic mutations or engineer desired changes in the genome. Nucleic acid drugs hold promise for treating a wide range of diseases, including genetic disorders, cancer, viral infections, and inflammatory conditions, offering potential advantages such as specificity, potency, and the ability to target previously ＂undruggable＂ targets. However, challenges remain in optimizing delivery methods, ensuring safety, and overcoming off-target effects to fully realize their therapeutic potential.

According to DIResearch's in-depth investigation and research, the global Nucleic Acid Drugs market size was valued at XX Million USD in 2024 and is projected to reach XX Million USD by 2032, with a CAGR of XX% (2025-2032). Notably, the China market has changed rapidly in the past few years. By 2024, China's market size is expected to be XX Million USD, representing approximately XX% of the global market share. By 2032, it is anticipated to grow further to XX Million USD, contributing XX% to the worldwide market share.

The major global  manufacturers of Nucleic Acid Drugs include Sarepta Therapeutics, Ionis Pharmaceuticals, Alnylam, Biogen, Nippon Shinyaku, Sobi, Novartis, BioNTech, Pfizer, Moderna Therapeutics, Jazz Pharmaceuticals, CureVac, Regulus Therapeutics, ProQR, Secarna, MiNA Therapeutics, Sylentis, Arrowhead, Silence Therapeutics, Dicerna etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.

This report studies the market size, price trends and future development prospects of Nucleic Acid Drugs. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major manufacturers, as well as the market status and trends of different product types and applications in the global Nucleic Acid Drugs market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.

The regions and countries in the report include North America, Europe, China, APAC (excl. China), Latin America and Middle East and Africa, covering the Nucleic Acid Drugs market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Nucleic Acid Drugs industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.  

The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.

Global Key Manufacturers of Nucleic Acid Drugs Include:

Sarepta Therapeutics

Ionis Pharmaceuticals

Alnylam

Biogen

Nippon Shinyaku

Sobi

Novartis

BioNTech

Pfizer

Moderna Therapeutics

Jazz Pharmaceuticals

CureVac

Regulus Therapeutics

ProQR

Secarna

MiNA Therapeutics

Sylentis

Arrowhead

Silence Therapeutics

Dicerna

Nucleic Acid Drugs Product Segment Include:

Antisense Oligonucleotides (ASO)

siRNA

mRNA

Nucleic Acid Drugs Product Application Include:

Neuromuscular Diseases

hATTR

COVID-19

Others

Chapter Scope

Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trends

Chapter 2: Global Nucleic Acid Drugs Industry PESTEL Analysis

Chapter 3: Global Nucleic Acid Drugs Industry Porter’s Five Forces Analysis

Chapter 4: Global Nucleic Acid Drugs Major Regional Market Size and Forecast Analysis

Chapter 5: Global Nucleic Acid Drugs Market Size and Forecast by Type and Application Analysis

Chapter 6: North America Passenger Nucleic Acid Drugs Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 7: Europe Nucleic Acid Drugs Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 8: China Nucleic Acid Drugs Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 9: APAC (Excl. China) Nucleic Acid Drugs Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 10: Latin America Nucleic Acid Drugs Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 11: Middle East and Africa Nucleic Acid Drugs Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 12: Global Nucleic Acid Drugs Competitive Analysis of Key Manufacturers (Revenue, Market Share, Regional Distribution and Industry Concentration)

Chapter 13: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)

Chapter 14: Industrial Chain Analysis, Include Raw Material Suppliers, Distributors and Customers

Chapter 15: Research Findings and Conclusion

Chapter 16: Methodology and Data Sources